Recent Updates
Recently added Catalysts
WGS Positive Sentiment

GeneDx to Participate in Upcoming March 2026 Investor Conferences

Key Takeaway: GeneDx will participate in two upcoming investor conferences in March 2026. The events include a fireside chat on March 2 and a presentation on March 11, both of which will be available via live and archived webcasts. This participation highlights GeneDx's commitment to engaging with investors and showcasing its advancements in genomic diagnostics.
Price reaction · baseline $78.9 (2026-02-25 close) · hit pre-market · clean, no other WGS news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • GeneDx is a leader in rare disease diagnosis.
  • The company is leveraging genomic data for health improvements.
  • Upcoming investor conferences indicate strong engagement with stakeholders.

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:
Fireside Chat: Monday, March 2 at 1:50 p.m. ET
Presentation: Wednesday, March 11 at 3:00 p.m. ET
Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website atir.genedx.com/news-events/events.
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity™ also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visitgenedx.comand connect with us onLinkedIn,Facebook, and Instagram.

Frequently Asked Questions

When will GeneDx participate in investor conferences?

GeneDx will participate in investor conferences on March 2 and March 11, 2026.

What is the purpose of the upcoming conferences?

The conferences aim to engage with investors and showcase GeneDx's advancements in genomic diagnostics.

Where can I watch the presentations?

Live and archived webcasts of the presentations will be available on GeneDx's investor relations website.

What is GeneDx known for?

GeneDx is known for its leadership in rare disease diagnosis and genomic data utilization.

Last updated: Feb 26, 2026